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doi:10.1Objective: Infants undergoing heart transplantation have the highest early posttransplant mortality of any age
group. We sought to determine the pretransplantation factors associated with in-hospital mortality in trans-
planted infants in the current era.
Methods: All infants under 12 months of age who underwent primary heart transplantation during a recent
10-year period (1999–2009) in the United States were identified using the Organ Procurement and Transplant
Network database. Multivariable logistic regression was used to identify independent pretransplantation factors
associated with in-hospital mortality.
Results: Of 730 infants in the study (median age 3.8 months), 462 (63%) had congenital heart disease, 282
(39%) were supported by a ventilator, 94 (13%) with extracorporeal membrane oxygenation, and 22 (3%)
with a ventricular assist device at the time of transplantation. Overall, 82 (11.2%) infants died before their initial
hospital discharge. In adjusted analysis, in-hospital mortality was associated with repaired congenital heart dis-
ease (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.8, 7.2), unrepaired congenital heart disease not on
prostaglandin E (OR, 2.8; CI, 1.3, 6.1), extracorporeal membrane oxygenator support (OR, 6.1; CI, 2.8, 13.4),
ventilator support (OR, 4.4; CI, 2.3, 8.3), creatinine clearance less than 40 mL $ min1 $ 1.73 m2 (OR, 3.1; CI,
1.7, 5.3), and dialysis (OR, 6.2; CI, 2.1, 18.3) at transplantation.
Conclusions:One in 9 infants undergoing heart transplantation dies before hospital discharge. Pretranplantation
factors associated with early mortality include congenital heart disease, extracorporeal membrane oxygenator
support, mechanical ventilation, and renal failure. Risk stratification for early posttransplant mortality among
infants listed for heart transplantation may improve decision-making for transplant eligibility, organ allocation,
and posttransplant interventions to reduce mortality. (J Thorac Cardiovasc Surg 2011;141:531-6)Supplemental material is available online.
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est earlymortality of all children undergoingHT.1,2However,
those who survive the early period have the best long-term
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Xfourth of pediatric heart transplants performed in the
United States, reduction in early posttransplant mortality in
this group not only will improve long-term survival in infants
undergoing HT but also will benefit overall pediatric HT
survival.
Although age has been evaluated as a risk factor for early
posttransplant mortality within the broad context of pediat-
ric HT, few studies have focused on the infant population
alone. Infants undergoing HT are unique by virtue of the
prevalence of congenital heart disease (CHD) compared
with older children, their internal heterogeneity with respect
to prostaglandin-dependent circulation, and their exposure
to cardiac surgery.3,4 In addition, infants’ size constraints
result in a relative scarcity of donor organs and long
waiting times before HT, which may increase the risk of
end-organ dysfunction from prolonged exposure to insuffi-
cient organ perfusion and complications from medications
used to support cardiac function.5 Moreover, most previous
studies have analyzed mortality at arbitrary intervals
after HT, which may have been useful to assess center per-
formance1,3,4,6 but may not be optimal for designing
strategies to improve early posttransplant outcomes. In-
hospital mortality as an end point is important, not only be-
cause hospital discharge after HT is a clinical milestone, butrdiovascular Surgery c Volume 141, Number 2 531
Abbreviations and Acronyms
CHD ¼ congenital heart disease
ECMO ¼ extracorporeal membrane oxygenation
HT ¼ heart transplantation
IQR ¼ interquartile range
OPTN ¼ Organ Procurement and
Transplantation Network
US ¼ United States
VAD ¼ ventricular assist device
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Xalso because an improved understanding of factors driving
early mortality in this high-risk group may influence deci-
sions about criteria and timing for listing and for emerging
mechanical support devices.
The purpose of this study, therefore, was to identify the
pretransplant factors associated with in-hospital mortality
among infants undergoing HT in the current era.METHODS
Study Population
All patients less than 12 months of age who underwent their first ortho-
topic HT in the United States (US) between January 20, 1999, and January
20, 2009, were identified in the Organ Procurement and Transplantation
Network (OPTN) database. The OPTN is an internally audited, mandatory,
solid-organ transplant registry that includes data on all solid-organ trans-
plants in the US as submitted by the members of the network. The US De-
partment of Health and Human Services provides oversight of the activities
of the OPTN contractor, the United Network for Organ Sharing. We ex-
cluded infants who underwent multivisceral transplantation. All children
were followed up from the time of HT until death or hospital discharge.
Study Definitions and Outcome Measures
The primary outcome measure was in-hospital mortality, defined as in-
fants who received heart transplants and died before their initial hospital
discharge. All clinical and demographic variables were defined at the
time of HT. Pretransplant mechanical cardiorespiratory support was cate-
gorized as extracorporeal membrane oxygenation (ECMO) support, venti-
lator support (without ECMO), or no support (neither ECMO nor ventilator
support). Creatinine clearance was calculated using the formula presented
by Schwartz and associates.7 We also assessed the primary cause of death
in infants who died.
Statistical Analysis
Summary statistics are presented as median (interquartile range [IQR])
or number (percent). Patient characteristics were compared among
diagnostic subgroups using the c2 test for categorical variables and the
Kruskal–Wallis test for continuous variables. Characteristics of patients
who died versus those who survived were compared by the Wilcoxon rank
sum test or c2 test, as appropriate. Hospital mortality rates are displayed
with 95% exact binomial confidence intervals. A multivariable logistic re-
gression model was used to identify independent factors associated with
in-hospital mortality. Only risk factors that were statistically significant at
the .05 levelwere retained in thefinalmodel.Analyseswere performed using
statistical software SAS version 9.1 (SAS Institute Inc, Cary, NC) and
STATA version 10.0 (StataCorp LP, College Station, Tex). All authors had
full access to the data and take responsibility for its integrity.532 The Journal of Thoracic and Cardiovascular SurgRESULTS
Study Cohort
A total of 730 infants underwent orthotopic HT in the US
during the study period. The baseline characteristics of
these infants are summarized in Table 1 and Figure E1.
The primary cardiac diagnosis was CHD in 462 (63%),
cardiomyopathy in 224 (30%), and other in 44 (6%) pa-
tients. The median age of the cohort was 3.8 months
(IQR, 1.7–6.6 months) and the median weight was 4.7 kg
(IQR, 3.6–6.0 kg). The median donor weight was 7.0 kg
(IQR, 5.0–10.0 kg), and the donor/recipient weight ratio
was 1.5 (IQR, 1.1–1.9). Overall, infants receiving heart
transplants due to CHD were younger (P < .001) and
smaller (P<.001 for weight and body surface area) than in-
fants listed for cardiomyopathy. Ninety-four (13%) infants
were supported by ECMO at the time of transplant, 213
(29%) were supported with mechanical ventilation without
ECMO, 22 (3%) were supported with a ventricular assist
device (VAD), 120 (16%) were receiving prostaglandin
E (PGE), and 20 (3%) were supported with dialysis. Of
the 113 patients with repaired CHD who were supported
with PGE, 20 carried the diagnosis of hypoplastic left heart
syndrome. Infants with CHD were more likely to have
a creatinine clearance less than 40 mL $ min1 $ 1.73 m2
(P ¼ .10), and infants with cardiomyopathy were more
likely to be using a VAD at the time of transplant (P<.001).In-Hospital Mortality
Eighty-two (11.2%) of 730 infants died before their hos-
pital discharge. Table 2 summarizes univariate variables of
early hospital mortality before discharge. Infants who died
were younger and smaller than survivors. Other factors as-
sociated with in-hospital mortality included ECMO or ven-
tilator support at HT, prior sternotomy, creatinine clearance
less than 40 mL $ min1 $ 1.73 m2, dialysis at the time of
HT, and a bloodstream infection within 2 weeks preceding
HT. VAD and PGE use were not associated with higher in-
hospital mortality and only 1 patient supported with a VAD
died; however, the total number of patients using a VAD
(n ¼ 22) was small.
Figure 1 summarizes unadjusted in-hospital mortality for
infants receiving heart transplants according to diagnosis
(Figure 1, A), level of invasive support (Figure 1, B), and re-
nal function (Figure 1, C). Infants with repaired CHD were
far more likely to die before hospital discharge than were
the infants with cardiomyopathy (21% vs 5%; P<.001).
A substantial increase in mortality was seen on the basis
of the level of invasive support, with patients supported
by ECMO having the highest mortality. Finally, infants
with renal failure, estimated by creatinine clearance less
than 40 mL $ min1 $ 1.73 m2, had a significantly worse
outcome than did those with creatinine clearance of
40 mL $ min1 $ 1.73 m2 or more.ery c February 2011
TABLE 1. Baseline characteristics of the infant cohort by cardiac diagnosis*
Congenital heart disease
Total
(n ¼ 730)
Repaired
(n ¼ 194)
Unrepaired, on
PGE (n ¼ 113)
Unrepaired, no
PGE (n ¼ 155)
CMP
(n ¼ 224)
Other
(n ¼ 44) P value
Recipient age (mo) 3.8 (1.7–6.6) 4.7 (1.7–7.4) 1.5 (0.7–2.7) 2.8 (1.3–4.6) 5.9 (3.7–8.4) 5.0 (2.3–7.7) <.001
Recipient weight (kg) 4.7 (3.6–6.0) 4.9 (3.6–6.2) 3.6 (3.2–4.3) 4.1 (3.4–5.0) 5.6 (4.7–6.8) 5.0 (4.1–6.2) <.001
Donor weight (kg) 7.0 (5.0–10.0) 7.0 (5.3–10.0) 6.0 (4.0–8.0) 6.0 (4.4–8.6) 7.7 (6.0–11.0) 7.0 (5.8–10.0) <.001
Donor/recipient
weight ratio
1.5 (1.1–1.9) 1.5 (1.2–1.9) 1.6 (1.1–2.0) 1.5 (1.1–2.0) 1.4 (1.1–1.8) 1.5 (1.1–2.0) .30
Recipient BSA (kg/m2) 0.27 (0.23–0.32) 0.28 (0.23–0.33) 0.23 (0.21–0.26) 0.24 (0.21–0.28) 0.31 (0.27–0.35) 0.28 (0.25–0.33) <.001
Donor BSA 0.35 (0.28–0.44) 0.36 (0.29–0.45) 0.31 (0.24–0.38) 0.32 (0.25–0.41) 0.38 (0.31–0.49) 0.35 (0.31–0.48) <.001
Donor/recipient
BSA ratio
1.3 (1.08–1.57) 1.30 (1.11–1.56) 1.35 (1.07–1.66) 1.35 (1.07–1.59) 1.26 (1.07–1.51) 1.26 (1.1–1.6) .41
Female sex 331 (45%) 71 (37%) 40 (35%) 67 (43%) 132 (59%) 21 (48%) <.001
Nonwhite race 265 (36%) 62 (32%) 41 (36%) 54 (35%) 93 (42%) 15 (34%) .35
Blood type O 326 (45%) 82 (42%) 51 (45%) 69 (45%) 102 (46%) 22 (50%) .90
PRA>10% 42 (14%) 16 (22%) 7 (14%) 6 (9%) 11 (12%) 2 (13%) .28
ABO-incompatible 54 (7%) 21 (11%) 8 (7%) 12 (8%) 9 (4%) 4 (9%) .10
ECMO 94 (13%) 51 (26%) 2 (2%) 8 (5%) 27 (12%) 6 (14%) <.001
Ventilator 213 (29%) 63 (32%) 31 (27%) 40 (26%) 66 (29%) 13 (30%) <.001
Neither ECMO
nor ventilator
423 (58%) 80 (41%) 80 (71%) 107 (69%) 131 (58%) 25 (57%) <.001
VAD 22 (3%) 0 (0%) 1 (1%) 2 (1%) 16 (7%) 3 (7%) <.001
PGE 120 (16%) 5 (3%) 113 (100%) 0 (0%) 1 (<1%) 1 (2%) <.001
Dialysis 20 (3%) 13 (7%) 1 (1%) 1 (1%) 3 (1%) 2 (5%) .002
Creatinine clearance
<40 mL $ min1 $
1.73 m2
141 (20%) 41 (22%) 28 (25%) 35 (24%) 31 (15%) 6 (14%) .10
BSI within 2 wk before
transplant
212 (31%) 74 (40%) 31 (28%) 33 (22%) 63 (30%) 11 (28%) .01
Prior sternotomy 101 (32%) 86 (100%) 0 (0%) 0 (0%) 7 (7%) 8 (47%) <.001
PGE, Prostaglandin E; CMP, cardiomyopathy; BSA, body surface area; PRA, panel of reactive antibodies; ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist
device; BSI, bloodstream infection. *All clinical variables defined at the time of heart transplantation. Total number of patients varies for each row due to incomplete data entry.
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XThe multivariable factors associated with in-hospital
mortality are presented in Table 3. Repaired CHD, unre-
paired CHD without PGE, ECMO support at HT, ventilator
support at HT, and renal failure (including creatinine
clearance< 40 mL $ min1 $ 1.73 m2 or dialysis at HT)
were independently associated with in-hospital mortality.
There was a significant increase in mortality if the primary
diagnosis was repaired CHD or unrepaired CHD without
PGE. Unrepaired CHD with PGE and VAD support at HT
were not significantly associated with in-hospital mortality
in the multivariable model.
Figure 2 depicts the observed hospital mortality rate for
infants undergoing HT in the presence of more than 1 risk
factor. The observed in-hospital mortality rate ranged from
as low as 3% (infants with cardiomyopathy not requiring in-
vasive hemodynamic support or dialysis) to as high as 78%
(infants supported by ECMOand requiring dialysis). Listing
status was not independently associated with posttransplant
outcome, perhaps because the vast majority of infants are
listed status 1A at the time of transplant (Figure E2).
The primary causes of death for infants who underwent
HT but failed to survive to hospital discharge are shownThe Journal of Thoracic and Cain Table E1. Non–rejection-related graft failure and end-
organ failure together accounted for nearly 60% of the early
infant deaths. Rejection-related graft failure accounted for
less than 10% of early deaths. In univariate analysis,
ECMO support was the only factor significantly associated
with death after hospital discharge (Table E2).
DISCUSSION
In this study we found that, in the current era, 11.2% of
infants undergoing HT fail to survive to hospital discharge,
a mortality rate that is approximately 50% higher than that
of older children receiving heart transplants. However, the
mortality rate is not constant across all infants but varies
by more than 20-fold (3% vs 78%) based on patient-
specific factors. Infants with repaired CHD or unrepaired
CHD not receiving PGE, those supported with ECMO or
mechanical ventilation, and those with renal failure at the
time of HT experienced increased mortality.
Several studies have analyzed factors associatedwith early
mortality in children undergoing HT.1,3,4,6,8-10 However,
analyses focusing on infants have been limited to single-
center experiences4 or multicenter experiences from therdiovascular Surgery c Volume 141, Number 2 533
TABLE 2. Univariate variables of in-hospital mortality after infant
heart transplantation*
Survived
(n ¼ 648)
Died
(n ¼ 82) P value
Age (mo) 3.9 (1.8–6.8) 2.5 (1.1–5.3) .004
Weight (kg) 5.0 (3.6–6.0) 4.0 (3.2–5.1) <.001
Donor weight (kg) 7.0 (5.0–10.0) 6.0 (4.0–8.0) .003
Donor/recipient
weight ratio
1.5 (1.1–1.9) 1.4 (1.1–1.9) .7
BSA 0.28 (0.23–0.32) 0.24(0.21–0.3) .001
Donor/recipient
BSA ratio
1.31 (1.08–1.57) 1.26 (1.04–1.57) .66
Ischemic time 3.8 (3.1–4.6) 4.1 (3.1–4.7) .12
Female sex 299 (46%) 32 (39%) .24
Nonwhite race 240 (37%) 25 (30%) .27
Blood type .42
Identical 475 (73%) 55 (67%)
Compatible 127 (20%) 19 (23%)
Incompatible 46 (7%) 8 (10%)
PRA>10% 40 (15%) 2 (7%) .39
Cardiac diagnosis <.001
CHD
Repaired 153 (24%) 41 (50%)
Unrepaired 138 (21%) 17 (21%)
Unrepaired on PGE 104 (16%) 9 (11%)
Cardiomyopathy 212 (33%) 12 (15%)
Other 41 (6%) 3 (4%)
Prior sternotomy 82 (29%) 19 (56%) .003
ECMO support 65 (10%) 29 (35%) <.001
Ventilator support 176 (27%) 16 (20%) <.001
Neither ECMO
nor ventilator
407 (63%) 16 (20%) <.001
VAD support 21 (3%) 1 (1%) .50
Dialysis support 7 (1%) 13 (16%) <.001
Creatinine clearance
<40 mL $ min1 $ m2
106 (17%) 35 (47%) <.001
BSI  2 wk before
transplant
176 (29%) 36 (47%) .001
BSA, Body surface area; PRA, panel of reactive antibodies; CHD, congenital heart
disease; PGE, prostaglandin E; ECMO, extracorporeal membrane oxygenation;
VAD, ventricular assist device; BSI, bloodstream infection. *All clinical variables de-
fined at the time of heart transplantation. FIGURE 1. Observed rates of in-hospital mortality after heart transplan-
tation. Infants with congenital heart disease (CHD) had a significantly
higher rate of in-hospital mortality than did those with cardiomyopathy
(A). Infants receiving extracorporeal membrane oxygenator (ECMO) sup-
port or ventilator support had a higher rate of in-hospital mortality than did
those without such support (B). Finally, infants with a creatinine clearance
less than 40 mL $ min1 $ 1.73 m2 had a significantly higher rate of in-
hospital mortality than did those with creatinine clearance greater than
40 mL $ min1 $ 1.73 m2 (C). PGE, Prostaglandin E.
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X 1990s,3 which may not be generalizable to all centers in cur-
rent times because of regional differences in practice and be-
cause of important changes in listing strategies such as ABO-
incompatible HT,11,12 increasing use of VAD therapy,13-15
United Network for Organ Sharing heart allocation policy
revisions,16 heart donation after cardiac death,17 and ad-
vances in post-HT management. To our knowledge, this is
the first multicenter analysis of early posttransplant mortality
specifically in infants and in the current era.
Prior studies in HT recipients have examined early post-
transplant mortality using a fixed time cutoff such as
30 days1,3,4,6 or 1 year after HT.1,3 Although both 30-day
mortality and in-hospital mortality are likely to be associ-
ated with similar risk factors, in-hospital mortality that534 The Journal of Thoracic and Cardiovascular Surgincludes deaths after 30 days is a better measure of
operative mortality18,19 and is likely to be more
homogeneous with respect to mechanisms compared with
mortality within 30 days (or any other specified interval)
that includes postdischarge deaths. Therefore, in addition
to its clinical importance, in-hospital mortality provides
a more accurate assessment of early mortality, andery c February 2011
TABLE 3. Multivariable variables of in-hospital mortality after infant
heart transplantation*
Odds ratio
(95% CI) P value
Diagnostic category
Repaired CHDy 3.6 (1.8, 7.2) <.001
Unrepaired CHD with PGEy 2.0 (0.8, 5.1) .14
Unrepaired CHD, no PGEy 2.8 (1.3, 6.1) .01
Advanced support
ECMO support 6.1 (2.8, 13.4) <.001
Ventilator 4.4 (2.3, 8.3) <.001
Renal function
Creatinine clearance
<40 mL $ min1 $ 1.73 m2
(vs>40)
3.1 (1.7, 5.3) <.001
Creatinine value not reported 3.9 (1.5, 10.3) .006
Dialysis at transplant 6.2 (2.1, 18.3) .001
CI, Confidence intervals; CHD, congenital heart disease; PGE, prostaglandin E;
ECMO, extracorporeal membrane oxygenation. *All clinical variables defined at
the time of heart transplantation. yReference group is structurally normal hearts (car-
diomyopathyþother).
Gandhi et al Cardiothoracic Transplantationdetermining which factors are associated with it may allow
for interventions to reduce pretransplant risk and improve
postoperative management.
We found a large heterogeneity in the observed rate of
hospital mortality indicating the need for a more accurate
risk stratification method using information present at the
time of HT. Such a stratification method may help refine
clinical decisions including defining the optimal timing
for listing and for heart transplant,20 de-listing because of
clinical deterioration,20 timing and clinical criteria for
emerging VAD technologies,21 and when transplant should
be considered clinically futile and/or unethical given the
scarcity of donor organs.22 For example, our findings sug-FIGURE 2. Observed in-hospital mortality for infants undergoing heart
transplantation by cardiac diagnosis, level of invasive hemodynamic sup-
port, and dialysis. Dialysis group and diagnosis groups are not mutually ex-
clusive. All infants (N ¼ 686). ECMO, Extracorporeal membrane
oxygenation; CMP, cardiomyopathy; CHD, congenital heart disease.
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Xgest it may be reasonable for a transplant center to defer list-
ing an infant on ECMO who requires dialysis because the
posttransplant early mortality for such an infant is estimated
at nearly 80% in the current era. Furthermore, these find-
ings may be useful in establishing a clearer clinical thresh-
old for listing, such as stable decannulation from ECMO
with renal recovery, or stable transition to a VAD with re-
covery of renal function23 such that the risk of hospital mor-
tality falls to more acceptable level. However, although
some patient-specific factors are strongly associated with
in-hospital mortality, decisions regarding proceeding to
HT or advising families and clinicians regarding prognosis
after HT should be based on the clinical context and the ex-
perience of the primary physician caring for the patient.
Our findings also underscore the exceedingly difficult
task that policymakers face when revising the current pedi-
atric heart allocation system. Because the most important
factors associated with early posttransplant death are nearly
identical to the most important factors associated with death
on the waiting list24 (eg, ECMO, ventilation, poor renal
function, CHD), it may be difficult for policymakers to de-
velop an allocation scheme that prioritizes candidates who
are simultaneously at a high level of medical urgency and
also highly likely to benefit from transplant, as is currently
done with the lung allocation scheme.25
Our analysis has several limitations. First, retrospective
analyses are inherently susceptible to selection bias if a non-
random sample population is used. However, because this
analysis included all infants undergoing first-time single-
organ HT in the US, no further selection bias was imposed.
Second, there were only 82 hospital deaths in the study
cohort, which resulted in relatively wide confidence inter-
vals when determining which factors were associated with
higher mortality. Furthermore, detailed anatomic and surgi-
cal diagnostic data for study infants were not available,
thereby limiting our ability to draw diagnosis-specific infer-
ences among infants with CHD. Additionally, the cause of
death was reported by the institutions and, therefore, poten-
tially contains reporting bias. Finally, although the identified
factors were associated with in-hospital mortality, the effect
of these factors on long-term mortality cannot be assumed.
In summary, 1 in 9 infants undergoing HT does not sur-
vive to hospital discharge. The factors associated with in-
hospital death after transplant include cardiac diagnosis,
the level of invasive support, and renal function at the
time of transplant. These factors may be useful in making
decisions regarding timing of transplant listing, criteria
for de-listing, selection criteria for VAD support, and defin-
ing transplant futility.
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FIGUREE1. In-hospital mortality based on diagnosis at transplant.CHD,
Congenital heart disease; PGE, prostaglandin E.
FIGUREE2. Ten-year trend in status 1A listing among US infants at time
of heart transplantation. The number of infants listed status 1A has
increased and now almost all infants receive heart transplantation as
status 1A.
TABLEE1. Causeofdeath for infantsundergoingheart transplantation
who failed to survive to hospital discharge (N¼ 82)
N (%)
Graft failure, nonrejection 26 (31.7%)
End-organ failure 23 (28.0%)
Infection 8 (9.8%)
Hemorrhage 6 (7.3%)
Rejection 5 (6.1%)
Stroke 3 (3.6%)
Pulmonary embolism 1 (1.2%)
Coronary artery disease 1 (1.2%)
Other 9 (11%)
TABLE E2. Univariate analysis of factors associated with death after
hospital discharge*
Hazard
ratio 95% CI P value
Diagnostic category
Repaired CHDy 0.9 (0.6, 1.7) .87
Unrepaired CHD, with PGEy 1.0 (0.6, 1.8) .97
Unrepaired CHD, no PGEy 1.4 (0.9, 2.3) .15
Advanced support
ECMO 2.5 (1.4, 4.4) .001
Ventilator 1.3 (0.8, 2.0) .25
Renal function
Dialysis at time of transplant 0.9 (0.1, 6.1) .88
Creatinine clearance
<40 mL $ min1 $ m2
1.1 (0.7, 1.9) .64
Creatinine value not reported 1.6 (0.8, 3.1) .20
CI, Confidence intervals; CHD, congenital heart disease; PGE, prostaglandin E;
ECMO, extracorporeal membrane oxygenation. *All clinical variables defined at
the time of heart transplantation. yReference group is structurally normal hearts (car-
diomyopathyþother).
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